HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: ps.035576.108v1 ps.035576.108v2 17/9/1586    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Peroutka, R. J. Articles by Butt, T. R. PubMed PubMed Citation Articles by Peroutka, R. J. Articles by Butt, T. R. Social Bookmarking                   What's this?

Enhanced protein expression in mammalian cells using engineered SUMO fusions: Secreted phospholipase A₂

LifeSensors, Inc., Malvern, Pennsylvania 19355, USA

(RECEIVED April 3, 2008; FINAL REVISION June 4, 2008; ACCEPTED June 4, 2008)

SUMOylation, the covalent attachment of SUMO (small ubiquitin-like modifier), is a eukaryotic post-translational event that has been demonstrated to play a critical role in several biological processes. When used as an N-terminal tag or fusion partner, SUMO has been shown to enhance functional protein production significantly by improving folding, solubility, and stability. We have engineered several SUMOs and, through their fusion, developed a system for enhancing the expression and secretion of complex proteins. To demonstrate the fidelity of this fusion technology, secreted phospholipase A₂ proteins (sPLA₂) were produced using HEK-293T and CHO-K1 cells. Five mouse sPLA₂ homologs were expressed and secreted in mammalian cell cultures using SUMO or SUMO-derived, N-terminal fusion partners. Mean and median increases of 43- and 18-fold, respectively, were obtained using novel SUMO mutants that are resistant to digestion by endogenous deSUMOylases.

Keywords: SUMO; SUMO fusion; phospholipase A₂ ; mammalian expression; deSUMOylase

CiteULike

Connotea

Del.icio.us

Digg

Reddit

Technorati